Resources for Patients and Caregivers
Symptoms that occur when someone stops using alcohol after a period of heavy drinking. Symptoms of alcohol withdrawal can vary widely in severity. In severe cases, the condition can be life-threatening.
Symptoms may occur from two hours to four days after stopping alcohol. They may include headaches, nausea, tremors, anxiety, hallucinations, and seizures.
In many cases, alcohol withdrawal requires medical treatment and hospital admissions. Medications may be used to treat physical symptoms while counseling and support groups help with controlling drinking behavior.
Wiki Number: 05-Alcohol Withdrawal
Diagnosis: Alcohol Withdrawal
Brain Area: May alter genetics and GABA receptors In the brain. May have prolonged withdrawal due to dopamine underactivity.
Symptoms: anxiety, shakiness, sweating, vomiting, hallucinations and delerium
Progression: Start about six hours after the last drink, worst at 24-72 hours, improve by seven days.
Medications: Benzodiazepines but these also have negative side effects.
Resources for Physicians, Counselors and Researchers
4 CURRENT ARTICLES
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Phenobarbital for the management of severe acute alcohol withdrawal (the PHENOMANAL trial): a pilot randomized controlled trialby Niall Filewod on January 23, 2022
BACKGROUND: Benzodiazepines are considered first-line treatment for patients experiencing severe acute alcohol withdrawal syndrome (sAAWS). Although several medications have been evaluated as potential adjuvant treatments for sAAWS, barbiturates show particular promise.
- Peer support for discharge from inpatient mental health care versus care as usual in England (ENRICH): a parallel, two-group, individually randomised controlled trialby Steve Gillard on January 23, 2022
BACKGROUND: High numbers of patients discharged from psychiatric hospital care are readmitted within a year. Peer support for discharge has been suggested as an approach to reducing readmission post-discharge. Implementation has been called for in policy, however, evidence of effectiveness from large rigorous trials is missing. We aimed to establish whether peer support for discharge reduces readmissions in the year post-discharge.
- Mirtazapine for the treatment of amphetamine and methamphetamine use disorder: A systematic review and meta-analysisby Leen Naji on January 23, 2022
CONCLUSIONS AND RELEVANCE: Mirtazapine probably results in a small reduction in continued methamphetamine use among cisgender men and transgender women with AMD, but probably does not improve patients' retention in treatment or depression symptom severity.
- GLP-1a: Going beyond Traditional Useby Lucas Fornari Laurindo on January 21, 2022
Glucagon-like peptide-1 (GLP-1) is a human incretin hormone derived from the proglucagon molecule. GLP-1 receptor agonists are frequently used to treat type 2 diabetes mellitus and obesity. However, the hormone affects the liver, pancreas, brain, fat cells, heart, and gastrointestinal tract. The objective of this study was to perform a systematic review on the use of GLP-1 other than in treating diabetes. PubMed, Cochrane, and Embase were searched, and the PRISMA guidelines were followed....